Aktieanalys

Nanexa: NEX-22 Progress, Revaluation and Financing - Emergers

Emergers Publicerad: 28 Aug 09:36

After initiating dosing of the first patient in June with Nanexa’s long-acting depot formulation of the GLP-1 analog liraglutide, NEX-22 for the treatment of type 2 diabetes, phase I is now progressing with the second cohort, according to plan. We now look forward to the outcome from subsequent cohorts and the full Phase I in 2024, and Ib in late 2025, as well as the partner project with Novo Nordisk and other advanced evaluation projects. Since the dip following the CMD in May, the stock has undergone a remarkable revaluation and tripled in value. We continue to find support for a fair value of SEK 2.6-9.9 per share, not factoring in a rights issue, which is the likely scenario if a license deal fails to materialize within the next 6-9 months.

Länk till analysen i sin helhet: https://www.emergers.se/nanexa_x24/

Nyheter om Nanexa

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!